Clark JD, Flanagan ME, Telliez JB. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem. 2014;57(12):5023–38.

Article  PubMed  Google Scholar 

Le AM, Puig L, Torres T. Deucravacitinib for the treatment of psoriatic disease. Am J Clin Dermatol. 2022;23:813–22.

Article  PubMed  PubMed Central  Google Scholar 

Nogueira M, Puig L, Torres T. JAK inhibitors for treatment of psoriasis: focus on selective TYK2 inhibitors. Drugs. 2020;80(4):341–52.

Article  PubMed  Google Scholar 

Kim LS, Wu JJ, Han G. Deucravacitinib for psoriasis. Current Dermatology Reports. 2021;10(1):1–5.

Article  Google Scholar 

Bristol Myers Squibb. SOTYKTU™ (deucravacitinib) tablets, for oral use: US prescribing information. 2022. https://packageinserts.bms.com/pi/pi_sotyktu.pdf. Accessed 12 Sep 2022.

Bristol Myers Squibb. U.S. Food and Drug Administration approves Sotyktu™ (deucravacitinib), oral treatment for adults with moderate-to-severe plaque psoriasis [media release]. 9 Sept 2022. https://www.bms.com/

Catlett IM, Hu Y, Gao L, et al. Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis. J Allergy Clin Immunol. 2022;149(6):2010-20.e8.

Article  PubMed  Google Scholar 

Bristol Myers Squibb. Bristol Myers Squibbs applications for deucravacitinib for the treatment of moderate to severe plaque psoriasis accepted by U.S. Food and Drug Administration and validated by European Medicines Agency [media release]. 29 Nov 2021. https://www.bms.com/

Bristol-Myers Squibb K.K. Bristol-Myers Squibb K.K. received manufacturing and marketing approval for TYK2 inhibitor SOTYKTU® tablets 6 mg [media release]. 26 Sept 2022. https://www.bms.com/assets/bms/japan/pressrelease/20220926.pdf

Gillooly K, Zhang Y, Yang X, et al. BMS-986165 is a highly potent and selective allosteric inhibitor of Tyk2, blocks IL-12, IL-23 and type I interferon signaling and provides for robust efficacy in preclinical models of systemic lupus erythematosus and inflammatory bowel disease [abstract no. 11L]. Arthritis Rheumatol. 2016;68(Suppl 10).

Chimalakonda A, Burke J, Cheng L, et al. Selectivity profile of the tyrosine kinase 2 inhibitor deucravacitinib compared with Janus kinase 1/2/3 inhibitors. Dermatol Ther (Heidelb). 2021;11(5):1763–76.

Article  PubMed  PubMed Central  Google Scholar 

Xie JH, Gillooly K, Zhang Y, et al. BMS-986165 is a highly potent and selective allosteric inhibitor of Tyk2, blocks Il-12, Il-23 and type I interferon signaling and provides for robust efficacy in preclinical models of inflammatory bowel disease [abstract no. 349]. In: Digestive Disease Week. 2018.

Papp K, Gordon K, Thaçi D, et al. Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis. N Engl J Med. 2018;379(14):1313–21.

Article  PubMed  Google Scholar 

FitzGerald O, Gladman D, Mease P, et al. Biomarker changes with selective tyrosine kinase 2 inhibitor, deucravacitinib, in PsA: effects on disease markers and tyrosine kinase 2-versus Janus kinase 1/2/3-mediated pathways [abstract no. 0490]. Arthritis Rheumatol. 2021;73(Suppl 9):1013–5.

Chimalakonda A, Singhal S, Dockens R, et al. Deucravacitinib, a selective tyrosine kinase 2 (TYK2) inhibitor: overview of clinical pharmacology including ADME, food and pH effects, pharmacokinetics in special populations, and drug-drug interactions [poster no. P1336]. In: EADV 30th Congress. 2021.

Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2022. https://doi.org/10.1016/j.jaad.2022.07.002.

Article  PubMed  Google Scholar 

Strober B, Thaci D, Sofen H, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 POETYK PSO-2 trial. J Am Acad Dermatol. 2022. https://doi.org/10.1016/j.jaad.2022.08.061.

Article  PubMed  Google Scholar 

Warren RB, Armstrong A, Gooderham M, et al. Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy results from the phase 3 POETYK PSO-1 and POETYK PSO-2 trials [abstract no. AB0890]. Ann Rheum Dis. 2022;81(Suppl 1):1570.

Warren RB, Sofen H, Imafuku S, et al. Deucravacitinib long-term efficacy and safety in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program [abstract no. POS1046]. Ann Rheum Dis. 2022;81(Suppl 1).

Bristol Myers Squibb. New two-year deucravacitinib data reinforce durable efficacy and consistent safety profile in treatment of moderate to severe plaque psoriasis [media release]. 12 May 2022. http://www.bms.com

Bristol Myers Squibb. Bristol Myers Squibb announces new SotyktuTM (deucravacitinib) long-term data showing clinical efficacy maintained for up to two years with continuous treatment in moderate-to-severe plaque psoriasis [media release]. 10 Sep 2022. http://www.bms.com

Mease PJ, Deodhar AA, Van Der Heijde D, et al. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Ann Rheum Dis. 2022;81(6):815–22.

Article  PubMed  Google Scholar 

Morand E, Pike M, Merrill JT, et al. Efficacy and safety of deucravacitinib, an oral, selective, allosteric Tyk2 inhibitor, in patients with active systemic lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study [abstract no. LB0004]. Ann Rheum Dis. 2022;81(Suppl 1):209.

US National Institutes of Health. ClinicalTrials.gov identifier NCT0325258. 2022. https://clinicaltrials.gov/. Accessed 7 Oct 2022.

Danese S, Panaccione R, D’Haens G, et al. Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with moderately-to-severely active ulcerative colitis: 12-week results from the phase 2 LATTICE-UC study [abstract no. DOP42]. J Crohns Colitis. 2022;16:i091-i92.

Article  Google Scholar 

Armstrong A, Gooderham M, Warren RB, et al. Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, compared with placebo and apremilast in moderate to severe plaque psoriasis: results from the phase 3 POETYK PSO-1 study [abstract no. POS1042 plus poster]. Ann Rheum Dis. 2021;80(Suppl 1):795–6.